NEW YORK – The US Food and Drug Administration on Wednesday granted accelerated approval to Dizal's oral EGFR inhibitor Zegfrovy (sunvozertinib) as a treatment for patients with locally advanced or ...

Japan-based Takeda Pharmaceuticals, manufacturer of the second-generation dengue vaccine Qdenga, said it is just waiting for ...

A significant development in the treatment of advanced melanoma has recently emerged: tumor-infiltrating lymphocyte (TIL) ...

Alembic to expand their U.S. commercial portfolio with FDA-approved PIVYA for the treatment of women with uncomplicated ...